Verastem, Inc. (VSTM)
6.33
-0.53
(-7.73%)
USD |
NASDAQ |
Nov 20, 16:00
6.34
+0.01
(+0.16%)
After-Hours: 20:00
Verastem Research and Development Expense (TTM) : 180.04M for Sept. 30, 2026
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2026 | 180.04M |
| June 30, 2026 | 140.22M |
| March 31, 2026 | 123.67M |
| December 31, 2025 | 114.60M |
| September 30, 2025 | 103.74M |
| June 30, 2025 | 99.50M |
| March 31, 2025 | 92.78M |
| December 31, 2024 | 81.33M |
| September 30, 2024 | 83.02M |
| June 30, 2024 | 72.22M |
| March 31, 2024 | 67.05M |
| December 31, 2023 | 61.36M |
| September 30, 2023 | 49.59M |
| June 30, 2023 | 46.94M |
| March 31, 2023 | 48.93M |
| December 31, 2022 | 50.56M |
| September 30, 2022 | 51.21M |
| June 30, 2022 | 49.25M |
| March 31, 2022 | 44.09M |
| December 31, 2021 | 39.35M |
| September 30, 2021 | 38.10M |
| June 30, 2021 | 39.37M |
| March 31, 2021 | 38.99M |
| December 31, 2020 | 41.02M |
| September 30, 2020 | 43.32M |
| Date | Value |
|---|---|
| June 30, 2020 | 44.94M |
| March 31, 2020 | 46.94M |
| December 31, 2019 | 45.78M |
| September 30, 2019 | 42.08M |
| June 30, 2019 | 41.44M |
| March 31, 2019 | 42.47M |
| December 31, 2018 | 43.65M |
| September 30, 2018 | 46.14M |
| June 30, 2018 | 52.31M |
| March 31, 2018 | 48.97M |
| December 31, 2017 | 46.42M |
| September 30, 2017 | 42.06M |
| June 30, 2017 | 28.54M |
| March 31, 2017 | 23.98M |
| December 31, 2016 | 19.78M |
| September 30, 2016 | 20.58M |
| June 30, 2016 | 27.66M |
| March 31, 2016 | 34.22M |
| December 31, 2015 | 40.56M |
| September 30, 2015 | 42.56M |
| June 30, 2015 | 40.30M |
| March 31, 2015 | 37.56M |
| December 31, 2014 | 35.45M |
| September 30, 2014 | 33.56M |
| June 30, 2014 | 31.30M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 929.60M |
| Cytokinetics, Inc. | 383.50M |
| Inovio Pharmaceuticals, Inc. | 44.47M |
| Rigel Pharmaceuticals, Inc. | 54.59M |
| United Therapeutics Corp. | 703.20M |